title: Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients.
abstract: Infection because of herpes simplex virus (HSV) that is resistant to acyclovir (ACV) poses treatment challenges in hematopoietic cell transplant (HCT) patients. We present a series of patients with ACV-resistant HSV following HCT who were successfully treated with continuous infusion high-dose ACV after failing standard treatment regimens for ACV-resistant HSV.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
authors.forename: Janet H
authors.initials: JH
authors.lastname: Kim
authors.forename: Joanna M
authors.initials: JM
authors.lastname: Schaenman
authors.forename: Dora Y
authors.initials: DY
authors.lastname: Ho
authors.forename: Janice M Y
authors.initials: JM
authors.lastname: Brown
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D024921:Drug Resistance, Multiple, Viral; D024882:Drug Resistance, Viral; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D018139:Simplexvirus / Q000187:drug effects* / Q000302:isolation & purification; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000212:Acyclovir